ClinicalTrials.gg
Not yet recruitingNCT07870759Updated Oct 13, 2026

Efficacy and Safety of Combination Therapy Compared With Monotherapy in Patients With Benign Prostatic Hyperplasia

A Phase 3 interventional study of Finasteride 5 mg Tablet, single dose and Tamsulosin 0.4Mg Capsule in Benign Prostatic Hyperplasia, sponsored by Il-Yang Pharm. Co., Ltd.. Not yet recruiting. Open to male participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Il-Yang Pharm. Co., Ltd. · Phase 3, Interventional, and Treatment

Updated Oct 13, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
660
Allocation
Randomized
Ages
45 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing finasteride in Prostatic Hyperplasia — 1 open to participants now, 2 under way, 1 of them phase 3. Finasteride · Prostatic Hyperplasia.

Planned enrollment
2nd of 10
660 · median 75
Started
2026
the only one that year
Phase 3
5 of 10
1 open now
Registered
10th of 10
by date
Lead sponsor
1 of 10
Il-Yang Pharm. Co., Ltd.

Among the 10 studies testing finasteride in Prostatic Hyperplasia, this one is the 2nd largest by planned enrollment, is the only one that started in 2026, is one of 5 in phase 3, and was the 10th registered.

Prostatic Hyperplasia

828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

1 of the 10 studies testing finasteride in Prostatic Hyperplasia is open now.

About finasteride

Finasteride: first FDA approval 1992 (PROSCAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 45 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing finasteride in Prostatic Hyperplasia, or all of them as a file.
02

Study summary

Efficacy and Safety of Combination Therapy Compared With Monotherapy in Patients With Benign Prostatic Hyperplasia

Read the detailed description

Benign prostatic hyperplasia (BPH) is a common condition in men that can cause lower urinary tract symptoms, including difficulty urinating, weak urinary stream, urinary frequency, and nocturia. This study is designed to evaluate the efficacy and safety of combination therapy with finasteride and tamsulosin compared with monotherapy in patients with BPH.

Participants will be randomly assigned to receive either combination therapy with finasteride and tamsulosin, finasteride monotherapy, or tamsulosin monotherapy. The efficacy of the treatments will be evaluated by changes in urinary symptoms and other clinical measures, including the International Prostate Symptom Score (IPSS), prostate volume, maximum urinary flow rate (Qmax), post-void residual urine volume (PVR), and serum prostate-specific antigen (PSA) level. Safety will also be evaluated throughout the study.

03

Conditions studied

  • Benign Prostatic Hyperplasia

Browse trials for

Keywords

  • BPH
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Screening Eligibility Criteria:

    1. Men aged 45 years or older.
    2. Participants diagnosed with benign prostatic hyperplasia (BPH).
    3. Prostate volume of ≥30 mL as measured by transrectal ultrasonography (TRUS).
    4. Participants considered capable of completing the questionnaires.
    5. Participants who voluntarily agree to participate in the clinical trial and - provide written .
  • Randomization Eligibility Criteria

    1. Total International Prostate Symptom Score (total IPSS) of ≥13 points.
    2. Maximum urinary flow rate (Qmax) of ≥4 mL/sec and ≤15 mL/sec, with a minimum voided volume of ≥125 mL.
    3. Postvoid residual urine volume (PVR) of \<200 mL.

Exclusion criteria

Exclusion Criteria:

  1. Participants with to the medicinal product, its components, or sulfonamides.
  2. Participants with any of the following medical histories:

    • of the pelvic organs (bladder, prostate, or rectum).
    • Prostate surgery or other invasive procedures (e.g., robotic simple prostatectomy, radiofrequency therapy, or minimally invasive treatment).
    • Urethrotomy or other surgery that may affect urinary flow, or pelvic surgery.
    • Lower urinary tract instrumentation within 4 weeks prior to screening.
    • Acute urinary retention within 12 weeks prior to screening.
    • Symptomatic orthostatic hypotension.
    • Known alcohol or drug abuse.
  3. Participants with any of the following comorbidities:

    • Major depressive disorder.
    • arrhythmia.
    • Uncontrolled hypertension (systolic blood pressure >170 mm Hg or diastolic blood pressure >100 mm Hg).
    • Uncontrolled hypotension (systolic blood pressure \<90 mm Hg or diastolic blood pressure \<50 mm Hg).
    • Uncontrolled diabetes mellitus ( >9.0%).
    • Galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
    • Severe renal impairment (estimated [eGFR] \<30 mL/min according to the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] equation).
    • Severe hepatic impairment ( and/or ALT >3 × ).
    • Conditions other than BPH that may cause voiding dysfunction or changes in urinary flow (e.g., neurogenic bladder, bladder neck sclerosis, urethral stricture, bladder tumor, acute or chronic prostatitis, or acute or chronic urinary tract infection).
  4. PSA >4.0 ng/mL, unless a prostate performed within 6 months prior to randomization confirms the absence of prostate cancer.
  5. Participants who underwent a prostate biopsy within 4 weeks prior to screening. Participants may be eligible if more than 4 weeks have elapsed since the biopsy.
  6. Participants who have received or are receiving any of the following medications or foods within the specified periods prior to randomization:

    • α-blockers (tamsulosin, terazosin, doxazosin, alfuzosin, etc.): within 4 weeks prior to randomization.
    • PDE5 inhibitors (tadalafil, sildenafil, vardenafil, udenafil, mirodenafil, avanafil, etc.): within 4 weeks prior to randomization.
    • 5α-reductase inhibitors (finasteride, dutasteride):

      1. Finasteride: within 12 weeks prior to randomization.
      2. Dutasteride: within 24 weeks prior to randomization.
    • Antimuscarinic/anticholinergic agents (oxybutynin, propiverine, solifenacin, tolterodine, trospium, etc.): within 4 weeks prior to randomization.
    • β3-adrenergic agonists (mirabegron, vibegron): within 4 weeks prior to randomization.
    • Progestogen preparations: within 24 weeks prior to randomization.
    • Medications with antiandrogenic effects other than progestogen preparations (spironolactone, flutamide, bicalutamide, cimetidine, ketoconazole, etc.): within 24 weeks prior to randomization.
    • Strong inducers (carbamazepine, phenytoin, rifampin, St. John's wort, etc.): within 4 weeks prior to randomization.
    • Strong CYP3A4 inhibitors (clarithromycin, lopinavir/ritonavir, ritonavir, ketoconazole, itraconazole, grapefruit, grapefruit juice, etc.): within 4 weeks prior to randomization.
    • Desmopressin: within 4 weeks prior to randomization.
    • Cholinergic agents (bethanechol, carbachol, etc.): within 4 weeks prior to randomization.
  7. Participants who have received an investigational medicinal product or investigational medical device within 4 weeks or 5 half-lives, whichever is longer, prior to screening.
  8. Participants who do not agree to use the methods permitted in this clinical trial (see Section 8.4.6.1) or to refrain from sperm donation during the clinical trial and for 30 days after the last administration of the investigational medicinal product.
  9. Participants who intend to donate blood during the clinical trial or for 30 days after the last administration of the investigational medicinal product.
  10. Participants who are considered unsuitable for participation in the clinical trial by the investigator for other reasons.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
660 participants (estimated)

Study arms

  • Experimental
    Treatment

    Finasteride+Tamsulosin

    Drug: Finasteride 5 mg Tablet, single dose · Drug: Tamsulosin 0.4Mg Capsule

  • Active comparator
    Comparator 1

    Finasteride

    Drug: Finasteride 5 mg Tablet, single dose

  • Active comparator
    Comparator 2

    Tamsulosin

    Drug: Tamsulosin 0.4Mg Capsule

Interventions

06

What researchers measure

Primary outcomes

  1. Total IPSS

    Change from baseline in total International Prostate Symptom Score (total IPSS) at Week 48 after treatment

    Time frame: Baseline to week 48

Secondary outcomes

  1. Total IPSS

    Change from baseline in total International Prostate Symptom Score (total IPSS) at Weeks 4, 12, 24, and 36 after treatment

    Time frame: Baseline to Weeks 4, 12, 24 and 36

  2. IPSS Quality of Life

    Change from baseline in the International Prostate Symptom Score (IPSS) quality of life (QoL) score at Weeks 4, 12, 24, 36, and 48 after treatment

    Time frame: Baseline to Weeks 4, 12, 24, 36 and 48

  3. IPSS Voiding Symptoms

    Change from baseline in the IPSS voiding symptom domain score at Weeks 4, 12, 24, 36, and 48 after treatment

    Time frame: Baseline to Weeks 4, 12, 24, 36, and 48

  4. IPSS Storage Symptoms

    Change from baseline in the IPSS storage symptom domain score at Weeks 4, 12, 24, 36, and 48 after treatment

    Time frame: Baseline to Weeks 4, 12, 24, 36, and 48

  5. Prostate Volume

    Change from baseline in prostate volume at Week 48 after treatment

    Time frame: Baseline to Week 48

  6. Maximum Urinary Flow Rate (Qmax)

    Change from baseline in maximum urinary flow rate (Qmax) at Weeks 24 and 48 after treatment

    Time frame: Baseline to Weeks 24 and 48

  7. Postvoid Residual Urine Volume (PVR)

    Change from baseline in postvoid residual urine volume (PVR) at Weeks 24 and 48 after treatment

    Time frame: Baseline to Weeks 24 and 48

  8. Serum PSA

    Change from baseline in serum prostate-specific antigen (PSA) level at Weeks 24 and 48 after treatment

    Time frame: Baseline to Weeks 24 and 48

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — The sponsor does not plan to make individual participant data (IPD) available to other researchers.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Aug 2027, 9 months later.

Of 17 phase 3 interventional studies under Prostatic Hyperplasia, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 50. This study's planned 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2026
First posted
Oct 13, 2026
StartEst.
Nov 9, 2026
Primary completionEst.
Aug 31, 2027
CompletionEst.
Aug 31, 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07870759
Responsible party
Sponsor
First posted
Oct 13, 2026
Start date
Nov 9, 2026 (estimated)
Primary completion
Aug 31, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

SukWoong Kang, Sr. Researcher
Contact
swkang1@ilyang.co.kr
+82-2-570-3779

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Finasteride · Tamsulosin

Start the discussion